Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

OP0169 Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align)

(2014) J. Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0264 Ustekinumab Improves Physical Function, Quality of Life and Work Productivity of Patients With Active Psoriatic Arthritis who were NaÏVe To MTX, Despite MTX Therapy or Previously Treated with Anti-Tnfॅ: Results from Psummit I and Psummit II

(2014) P. Rahman et al.   ANNALS OF THE RHEUMATIC DISEASES

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

(2013) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI

(2012) Christian E Althoff et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

(2011) D. van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

(2011) I.-H. Song et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis

(2010) M. Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register

(2010) E. Lie et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

(2010) Yang Mei et al.   CLINICAL RHEUMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

(2009) Rajan P Nair et al.   NATURE GENETICS

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

(2008) C Lukas et al.   ANNALS OF THE RHEUMATIC DISEASES

Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

(2008) W P Maksymowych et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of interleukin-23 receptor variants with ankylosing spondylitis

(2008) Proton Rahman et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

(2008) Robert D. Inman et al.   ARTHRITIS AND RHEUMATISM

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Role of Th1 and Th17 cells in organ-specific autoimmunity

(2008) Valérie Dardalhon et al.   JOURNAL OF AUTOIMMUNITY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET